Diagnostic Network and Laboratory Feasibility
A laboratory can receive enough tests to appear financially viable and still fail as a diagnostic service. The test mix may require skills or quality controls that the planned site cannot sustain. Specimen transport may consume the promised turnaround time, while equipment downtime or reagent shortages may leave patients without a dependable alternative.
Diagnostic feasibility must connect market demand with the complete operating network. Marketways estimates referral demand, models sample journeys and tests whether location, capacity, workforce, quality and resilience can support the proposed service before management commits capital.
Define the diagnostic service and catchment
A business case cannot begin with total laboratory demand. Management must define which tests the network will provide, which patients and referring providers it will serve, where specimens will originate and how quickly results must return.
Marketways maps the proposed catchment, referral relationships, testing menu and service standards. We distinguish routine, urgent and specialist demand because each category places different requirements on collection, transport, equipment, staffing and result communication.
This definition establishes the feasible market. A nearby patient does not create accessible demand when the provider uses another referral pathway, the test requires a distant specialist facility or the required turnaround cannot be achieved.
Estimate demand beyond historical referrals
Current volumes reflect existing access, price, clinician behaviour and turnaround. Patients may forgo a test that is unavailable, while clinicians may refer to a distant provider because no local service exists. Historical referrals can therefore understate the demand that better access would reveal.
Conversely, a new site may transfer tests from another facility within the same network rather than create new volume. Marketways estimates unmet demand, new referrals and internal substitution separately. We use provider research, population need, current pathways, geography and observed volumes to build explicit assumptions.
The forecast includes uncertainty. Management can see which volume depends on established referral behaviour and which depends on a change that still requires evidence.
Represent the test mix rather than an average test
Two laboratories can process the same number of tests and face different economics. Test families differ in reagent cost, batch size, equipment, specialist skill, quality control, repeat rate and reporting requirement.
Marketways models material test groups separately. We include repeats, rejected specimens, send-outs and confirmatory tests because they consume resources and affect the patient journey. We also examine whether one high-volume test supports shared infrastructure or merely occupies an instrument that another service needs.
Average revenue and cost per test can conceal these constraints. Feasibility depends on the combination of tests and the way that combination uses fixed and variable resources.
Measure turnaround across the complete sample journey
Instrument processing forms only one part of turnaround. Patients and providers also depend on collection, labelling, transport, accession, preparation, validation and result communication.
Marketways maps timestamps and handoffs from the test order to the usable result. We identify where specimens wait, which batches create delay and how missing information or rejected samples cause rework. This prevents management from buying faster equipment when the main constraint lies in transport or validation.
The analysis also distinguishes laboratory turnaround from the time that matters to the clinical pathway. A result that leaves the analyser quickly but reaches the responsible team late does not meet the service need.
Compare centralised and distributed capacity
Centralisation can improve equipment utilisation, specialist coverage and consistency. However, it can increase transport dependency and delay access for remote locations. Distributed testing can shorten the journey while duplicating equipment, controls and scarce skills.
Marketways compares network options through demand, geography, test stability, turnaround and quality requirements. Some tests may remain at high-volume hubs, while routine or time-sensitive services sit closer to patients. The design may also use point-of-care testing where the operating and quality conditions support it.
The preferred network is rarely the option with the lowest processing cost alone. It must balance access, quality, timeliness and the cost of maintaining dependable capacity at each tier.
Verify that each site can sustain quality
A testing location needs more than an instrument and trained operator. It requires specimen controls, equipment maintenance, reagents, documented procedures, quality assurance, competency and traceable results.
Marketways includes these operating requirements in the feasibility model. We assess whether expected volume supports proficiency and whether the site can maintain required controls across the proposed menu. Low volume may weaken skill retention or make per-test quality costs material.
Marketways does not make laboratory accreditation, clinical or regulatory decisions. We help clients translate their approved standards and professional requirements into capacity, process, evidence and management controls for the proposed network.
Model capacity as a constrained system
Laboratory capacity depends on more than stated analyser throughput. Batch rules, maintenance, calibration, preparation, validation, staffing patterns and peak arrival times determine how many results the system can deliver within its service standard.
Marketways uses queuing, simulation and scenario analysis where the decision requires them. We test the interaction between test mix, arrival patterns, shifts and equipment. The analysis identifies the actual constraint and the demand level at which waiting begins to rise materially.
This system view prevents one improvement from moving the queue. Additional analyser capacity may transfer the bottleneck to accession, specialist review or result release.
Test resilience before relying on the network
Equipment failure, reagent shortage, transport disruption and sudden demand can interrupt diagnostic access. A highly utilised network may appear efficient until one failure removes its remaining capacity.
Marketways tests disruption scenarios and recovery routes. We examine alternative instruments, sites, suppliers, transport and referral agreements. The model records the volume, test stability and time limit associated with each fallback.
Resilience has an explicit cost, but the absence of resilience also has a consequence. Management can distinguish spare capacity that protects a material service from capacity that no credible scenario requires.
Stage investment when demand remains uncertain
Some feasibility assumptions become clearer only after a service begins. Referral conversion, local test mix and operating performance may remain uncertain even after careful research.
Marketways designs staged commitments where the service permits them. Management may begin with collection and referral, lease capacity, introduce a limited menu or reserve space for later expansion. Each stage has a decision date, evidence requirement and threshold for proceeding.
This approach preserves the option to learn without postponing every decision. It also prevents initial capital from becoming the reason to continue an operating model that later evidence does not support.
Use AI for bounded routing and exception preparation
A diagnostic network generates continual information about test demand, specimen status, equipment, capacity and turnaround. An AI workflow can identify a threatened service level, retrieve the relevant dependencies and prepare an approved routing or escalation option.
Marketways defines the data, rules, permissions and responsible reviewer. The workflow may coordinate administrative routing within approved conditions. It must not interpret a clinical result, change clinical priority or select a diagnostic action without authorised professional judgement.
Every proposed route should preserve specimen identity, quality status, source data and the reason for the exception. Speed cannot compensate for an untraceable or unsuitable transfer.
Evaluate viability across clinical, operating and financial results
A laboratory network succeeds when it provides accessible, timely and dependable results within a viable operating model. Financial contribution alone cannot establish that outcome, and a strong quality measure cannot establish that the service can sustain its costs.
Marketways combines access, turnaround, rejected samples, quality, utilisation, resilience, workforce, contribution and capital need. We test the preferred option across demand and disruption ranges rather than presenting one deterministic forecast.
The recommendation states the conditions under which the design remains viable. It also identifies the measures that management must monitor before expanding, redesigning or stopping the next stage.
A specialist-test expansion illustrates the decision
Suppose a provider plans to add a specialist test at a regional laboratory. Current send-out volumes appear sufficient, and a local instrument would reduce external fees. However, referrals may not arrive evenly, specialist validation is available on limited shifts and the assay requires batches that affect turnaround.
Marketways would separate transferred from newly captured demand, model batch formation and map the complete sample journey. Scenarios would compare local testing with scheduled referral to a central site and a staged option that begins with defined test categories.
Management could then see whether local operation improves usable turnaround, which staffing and quality controls it requires and what volume supports the service. The investment decision would reflect the complete diagnostic pathway rather than the purchase price and annual test count.
How Marketways develops the feasibility case
Marketways combines Business Feasibility Study, Market Research and Demand Assessment and Simulation and Scenario Analysis. We estimate catchment and referral demand, represent the test mix, map sample journeys and compare location, capacity, workforce, resilience and staged investment options.
The resulting business case tells management what demand the network can serve, which operating conditions it must sustain and when the evidence justifies each commitment.